Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
As the Senior Director, Marketing you will design and execute the Commercial roadmap that enables the successful potential U.S. launch of palazestrant, Olema’s lead program currently in Phase 3 for ER+ HER2- metastatic breast cancer. The ideal candidate will have experience in the commercialization of oral oncology therapies in breast cancer and a track record of leading successful oncology drug launches in the US. This role is based out of our San Francisco office and will require travel as needed.
What they're looking for
- Minimum of 8 years of progressive commercial experience at biotechnology and/or pharmaceutical companies
- Successful history of developing and executing marketing strategy plans and leading the launch of new oncology products in the US
- Demonstrated ability to leverage insights and analytics to deliver impactful marketing strategies and tactics
- Ability to influence effectively across an organization at all levels
- Experience developing strategies to win in competitive markets
- Experience thriving in a small company environment, with a hands-on and pragmatic leadership style
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs · San Francisco Bay Area